{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T19:27:59Z","timestamp":1787254079330,"version":"build-2736575974"},"reference-count":17,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cedars Cancer Foundation of the McGill University Health Centre"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) improve outcomes across multiple cancers but may cause immune-related adverse events, including ICI-induced diabetes (ICI-D). ICI-D typically presents abruptly with severe insulin deficiency, and published cases have largely described irreversible loss of endogenous insulin secretion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>We report a novel case of clinical and biochemical recovery of ICI-D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Following melanoma treatment with ipilimumab plus nivolumab, then nivolumab monotherapy, the patient developed abrupt-onset symptomatic hyperglycemia with mild ketosis and positive GAD and insulin autoantibodies, consistent with ICI-D. The patient subsequently received infliximab for ICI-related arthritis. Insulin requirements progressively declined, allowing discontinuation of insulin therapy. GAD antibodies normalized within \u223c2 months and later became undetectable. Urine C-peptide\u2013to\u2013creatinine ratios increased over time, consistent with endogenous insulin secretion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Recovery from ICI-D may occur. The temporal association suggests infliximab may have contributed, warranting further study as a potential disease-modifying therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc26-0700","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:00:11Z","timestamp":1782918011000},"page":"1669-1672","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor\u2013Induced Diabetes With Seroconversion of GAD Antibodies"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7983-1865","authenticated-orcid":false,"given":"Lillian Ruiheng","family":"Chen","sequence":"first","affiliation":[{"name":"The Christie NHS Foundation Trust 1 , Manchester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Cooksley","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust 1 , Manchester, U.K."},{"name":"University of Greater Manchester 2 , Bolton, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupinder","family":"Kochhar","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Medicine and Health, University of Manchester 3 , Manchester, U.K."},{"name":"Salford Care Organisation, Northern Care Alliance NHS Trust 4 , Salford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezhil Jothi","family":"Titus Raj","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust 1 , Manchester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust 1 , Manchester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safwaan","family":"Adam","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust 1 , Manchester, U.K."},{"name":"Faculty of Biology, Medicine and Health, University of Manchester 3 , Manchester, U.K."},{"name":"NIHR Manchester Biomedical Research Centre 5 , Manchester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026082014532347100_B1","doi-asserted-by":"crossref","first-page":"e35476","DOI":"10.1002\/cncr.35476","article-title":"Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a surveillance, epidemiology, and end results database-based study","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"key":"2026082014532347100_B2","doi-asserted-by":"crossref","first-page":"102254","DOI":"10.1016\/j.canep.2022.102254","article-title":"Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: a retrospective study from the United States database","volume":"81","author":"Adhikari","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"2026082014532347100_B3","doi-asserted-by":"crossref","first-page":"e2227211","DOI":"10.1001\/jamanetworkopen.2022.27211","article-title":"Analysis of cancer survival associated with immune checkpoint inhibitors after statistical adjustment: a systematic review and meta-analyses","volume":"5","author":"Lin","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026082014532347100_B4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026082014532347100_B5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"key":"2026082014532347100_B6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2025.5594","article-title":"Immune checkpoint inhibitor-induced diabetes across National Cancer Institute trials that included PD-1 or PD-L1 agents","volume":"12","author":"Quandt","year":"2026","journal-title":"JAMA Oncol"},{"key":"2026082014532347100_B7","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.2337\/dc20-0609","article-title":"Immune checkpoint inhibitor\u2013associated diabetes: a single-institution experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"key":"2026082014532347100_B8","doi-asserted-by":"crossref","first-page":"1229823","DOI":"10.3389\/fimmu.2023.1229823","article-title":"A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome","volume":"14","author":"Marsiglio","year":"2023","journal-title":"Front Immunol"},{"key":"2026082014532347100_B9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026082014532347100_B10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s001250051067","article-title":"Autoantibodies associated with type I diabetes mellitus persist after diagnosis in children","volume":"41","author":"Savola","year":"1998","journal-title":"Diabetologia"},{"key":"2026082014532347100_B11","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.3760\/cma.j.issn.0366-6999.20130841","article-title":"Change of glutamic acid decarboxylase antibody and protein tyrosine phosphatase antibody in Chinese patients with acute-onset type 1 diabetes mellitus","volume":"126","author":"Chao","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"2026082014532347100_B12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1651-2227.2000.tb01186.x","article-title":"Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies\/IA2 antibodies after diagnosis of diabetes","volume":"89","author":"Borg","year":"2000","journal-title":"Acta Paediatr"},{"key":"2026082014532347100_B13","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"2026082014532347100_B14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jdi.13927","article-title":"Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: a case report","volume":"14","author":"Okubo","year":"2023","journal-title":"J Diabetes Investig"},{"key":"2026082014532347100_B15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00415-025-13157-2","article-title":"Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review","volume":"272","author":"Pignolo","year":"2025","journal-title":"J Neurol"},{"key":"2026082014532347100_B16","doi-asserted-by":"crossref","first-page":"1697724","DOI":"10.3389\/fendo.2025.1697724","article-title":"Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients","volume":"16","author":"Savion Gaiger","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026082014532347100_B17","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.2337\/dc19-0908","article-title":"Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab","volume":"42","author":"Trinh","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/9\/1669\/887861\/dc260700.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/9\/1669\/887861\/dc260700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:53:44Z","timestamp":1787252024000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/9\/1669\/172129\/Clinical-and-Biochemical-Recovery-From-Immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc26-0700","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}